For years, experts have expressed worries about the reactive nature of emerging disease vaccine development, most recently with the Zika outbreak. But even after the WHO stopped classifying Zika as an "emergency" in late 2016, Takeda pressed ahead with its program, this week winning the FDA's fast track designation.Original Article
Takeda’s Zika vaccine candidate wins FDA fast track status
